vs
Fabrinet（FN）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
Fabrinet的季度营收约是登士柏西诺德的1.2倍（$1.1B vs $961.0M），Fabrinet净利率更高（9.9% vs -15.2%，领先25.1%），Fabrinet同比增速更快（35.9% vs 6.2%），登士柏西诺德自由现金流更多（$60.0M vs $-5.3M），过去两年Fabrinet的营收复合增速更高（24.4% vs 0.4%）
Fabrinet（股票代码FN）为标普中型股400指数成分股。该指数由标普道琼斯指数公司维护，覆盖400家以美企为主的中等市值企业，若成分企业存在多类流通股，指数的成分股总量有时会超过400只。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
FN vs XRAY — 直观对比
营收规模更大
FN
是对方的1.2倍
$961.0M
营收增速更快
FN
高出29.7%
6.2%
净利率更高
FN
高出25.1%
-15.2%
自由现金流更多
XRAY
多$65.3M
$-5.3M
两年增速更快
FN
近两年复合增速
0.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $961.0M |
| 净利润 | $112.6M | $-146.0M |
| 毛利率 | 12.2% | 46.1% |
| 营业利润率 | 10.1% | -14.5% |
| 净利率 | 9.9% | -15.2% |
| 营收同比 | 35.9% | 6.2% |
| 净利润同比 | 30.0% | 66.0% |
| 每股收益（稀释后） | $3.11 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNXRAY
| Q4 25 | $1.1B | $961.0M | ||
| Q3 25 | $978.1M | $904.0M | ||
| Q2 25 | $909.7M | $936.0M | ||
| Q1 25 | $871.8M | $879.0M | ||
| Q4 24 | $833.6M | $905.0M | ||
| Q3 24 | $804.2M | $951.0M | ||
| Q2 24 | $753.3M | $984.0M | ||
| Q1 24 | $731.5M | $953.0M |
净利润FNXRAY
| Q4 25 | $112.6M | $-146.0M | ||
| Q3 25 | $95.9M | $-427.0M | ||
| Q2 25 | $87.2M | $-45.0M | ||
| Q1 25 | $81.3M | $20.0M | ||
| Q4 24 | $86.6M | $-430.0M | ||
| Q3 24 | $77.4M | $-494.0M | ||
| Q2 24 | $81.1M | $-4.0M | ||
| Q1 24 | $80.9M | $18.0M |
毛利率FNXRAY
| Q4 25 | 12.2% | 46.1% | ||
| Q3 25 | 11.9% | 48.8% | ||
| Q2 25 | 12.2% | 52.4% | ||
| Q1 25 | 11.7% | 53.0% | ||
| Q4 24 | 12.1% | 49.3% | ||
| Q3 24 | 12.3% | 52.1% | ||
| Q2 24 | 12.3% | 51.9% | ||
| Q1 24 | 12.4% | 53.1% |
营业利润率FNXRAY
| Q4 25 | 10.1% | -14.5% | ||
| Q3 25 | 9.6% | -24.1% | ||
| Q2 25 | 9.8% | -13.7% | ||
| Q1 25 | 9.0% | 7.2% | ||
| Q4 24 | 9.5% | -56.2% | ||
| Q3 24 | 9.6% | -48.6% | ||
| Q2 24 | 9.7% | 5.1% | ||
| Q1 24 | 9.7% | 4.4% |
净利率FNXRAY
| Q4 25 | 9.9% | -15.2% | ||
| Q3 25 | 9.8% | -47.2% | ||
| Q2 25 | 9.6% | -4.8% | ||
| Q1 25 | 9.3% | 2.3% | ||
| Q4 24 | 10.4% | -47.5% | ||
| Q3 24 | 9.6% | -51.9% | ||
| Q2 24 | 10.8% | -0.4% | ||
| Q1 24 | 11.1% | 1.9% |
每股收益（稀释后）FNXRAY
| Q4 25 | $3.11 | $-0.74 | ||
| Q3 25 | $2.66 | $-2.14 | ||
| Q2 25 | $2.41 | $-0.22 | ||
| Q1 25 | $2.25 | $0.10 | ||
| Q4 24 | $2.38 | $-2.09 | ||
| Q3 24 | $2.13 | $-2.46 | ||
| Q2 24 | $2.22 | $-0.02 | ||
| Q1 24 | $2.21 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $960.8M | $326.0M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $2.2B | $1.3B |
| 总资产 | $3.3B | $5.4B |
| 负债/权益比越低杠杆越低 | — | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资FNXRAY
| Q4 25 | $960.8M | $326.0M | ||
| Q3 25 | $968.8M | $363.0M | ||
| Q2 25 | $934.2M | $359.0M | ||
| Q1 25 | $950.7M | $398.0M | ||
| Q4 24 | $934.6M | $272.0M | ||
| Q3 24 | $908.9M | $296.0M | ||
| Q2 24 | $858.6M | $279.0M | ||
| Q1 24 | $794.0M | $291.0M |
总债务FNXRAY
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FNXRAY
| Q4 25 | $2.2B | $1.3B | ||
| Q3 25 | $2.1B | $1.5B | ||
| Q2 25 | $2.0B | $2.0B | ||
| Q1 25 | $1.9B | $2.0B | ||
| Q4 24 | $1.8B | $1.9B | ||
| Q3 24 | $1.8B | $2.5B | ||
| Q2 24 | $1.7B | $3.1B | ||
| Q1 24 | $1.7B | $3.3B |
总资产FNXRAY
| Q4 25 | $3.3B | $5.4B | ||
| Q3 25 | $3.0B | $5.7B | ||
| Q2 25 | $2.8B | $6.1B | ||
| Q1 25 | $2.6B | $6.0B | ||
| Q4 24 | $2.5B | $5.8B | ||
| Q3 24 | $2.4B | $6.6B | ||
| Q2 24 | $2.3B | $6.9B | ||
| Q1 24 | $2.2B | $7.1B |
负债/权益比FNXRAY
| Q4 25 | — | 1.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.3M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $-5.3M | $60.0M |
| 自由现金流率自由现金流/营收 | -0.5% | 6.2% |
| 资本支出强度资本支出/营收 | 4.6% | 4.3% |
| 现金转化率经营现金流/净利润 | 0.41× | — |
| 过去12个月自由现金流最近4个季度 | $102.3M | $104.0M |
8季度趋势，按日历期对齐
经营现金流FNXRAY
| Q4 25 | $46.3M | $101.0M | ||
| Q3 25 | $102.6M | $79.0M | ||
| Q2 25 | $55.1M | $48.0M | ||
| Q1 25 | $74.2M | $7.0M | ||
| Q4 24 | $115.9M | $87.0M | ||
| Q3 24 | $83.2M | $141.0M | ||
| Q2 24 | $83.1M | $208.0M | ||
| Q1 24 | $100.9M | $25.0M |
自由现金流FNXRAY
| Q4 25 | $-5.3M | $60.0M | ||
| Q3 25 | $57.3M | $40.0M | ||
| Q2 25 | $4.7M | $16.0M | ||
| Q1 25 | $45.7M | $-12.0M | ||
| Q4 24 | $94.0M | $36.0M | ||
| Q3 24 | $62.9M | $98.0M | ||
| Q2 24 | $70.4M | $156.0M | ||
| Q1 24 | $87.3M | $-9.0M |
自由现金流率FNXRAY
| Q4 25 | -0.5% | 6.2% | ||
| Q3 25 | 5.9% | 4.4% | ||
| Q2 25 | 0.5% | 1.7% | ||
| Q1 25 | 5.2% | -1.4% | ||
| Q4 24 | 11.3% | 4.0% | ||
| Q3 24 | 7.8% | 10.3% | ||
| Q2 24 | 9.3% | 15.9% | ||
| Q1 24 | 11.9% | -0.9% |
资本支出强度FNXRAY
| Q4 25 | 4.6% | 4.3% | ||
| Q3 25 | 4.6% | 4.3% | ||
| Q2 25 | 5.5% | 3.4% | ||
| Q1 25 | 3.3% | 2.2% | ||
| Q4 24 | 2.6% | 5.6% | ||
| Q3 24 | 2.5% | 4.5% | ||
| Q2 24 | 1.7% | 5.3% | ||
| Q1 24 | 1.9% | 3.6% |
现金转化率FNXRAY
| Q4 25 | 0.41× | — | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 0.63× | — | ||
| Q1 25 | 0.91× | 0.35× | ||
| Q4 24 | 1.34× | — | ||
| Q3 24 | 1.07× | — | ||
| Q2 24 | 1.02× | — | ||
| Q1 24 | 1.25× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FN
| Optical Communications | $832.6M | 73% |
| Non Optical Communications | $300.3M | 27% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
